다낭성 난소 증후군

키워드

참고문헌 (102)

1. Stein IF, "Amenorrhea associated with bilateral polycystic ovaries", Am J Obstet Gynecol, 29, pp.181~191 (1935)
2. Rebar R, "Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome", J Clin Invest, 57, pp.1320~1329 (1976)
3. Zawadzki JK, "Diagnostic criteria for polycystic ovary syndrome: towards a rational approach, In Polycystic Ovary Syndrome. 3rd ed", pp.377~384 (1992), Blackwell Scientific Publications
4. The Rotterdam ESHRE, "ASRM-Sponsored PCOS Consensus Workshop Group", Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome, 2004, pp.81, 19~25
5. The Rotterdam ESHRE, "ASRM –Sponsored PCOS consensus workshop group", Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS), 2004, pp.19, 41~47
6. Azziz R, "Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline", J Clin Endocrinol Metab, 91, pp.4237~4245 (2006)
7. Azziz R, "The polycystic ovary syndrome: current concepts on pathogenesis and clinical care", pp.1~60 (2007), Springer
8. Azziz R, "Androgen excess in women: Experience with over 1000 consecutive patients", J Clin Endocrinol Metab, 89, pp.453~462 (2004)
9. Legro RS, "Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome", Am J Med, 111, pp.607~613 (2001)
10. Carmina E, "Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet", Hum Reprod, 18, pp.2289~2293 (2003)
11. Hahn S, "Clinical and biochemical characterization of women with polycystic ovary syndrome in North Rhine-Westphalia", Horm Metab Res, 37, pp.438~444 (2005)
12. DeUgarte CM, "Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment", Fertil Steril, 83, pp.1454~1460 (2005)
13. Legro RS, "A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome", J Clin Endocrinol Metab, 83, pp.2694~2698 (1998)
14. Legro RS, "Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women", J Clin Endocrinol Metab, 84, pp.165~169 (1999)
15. Rebar R, "Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome", J Clin Invest, 57, pp.1320~1329 (1976)
16. Conway GS, "Heterogeneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 patients", Clin Endocrinol (Oxf), 30, pp.459~470 (1989)
17. Anttila L, "Clinical features and circulating gonadotropin, insulin, and androgen interactions in women with polycystic ovarian disease", Fertil Steril, 55, pp.1057~1061 (1991)
18. van Santbrink EJ, "Classification of normogonadotropic infertility: polycystic ovaries diagnosed by ultrasound versus endocrine characteristics of polycystic ovary syndrome", Fertil Steril, 67, pp.452~458 (1997)
19. Arroyo A, "Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity", J Clin Endocrinol Metab, 82, pp.3728~3733 (1997)
20. Taylor AE, "Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome", J Clin Endocrinol Metab, 82, pp.2248~2256 (1997)
21. Behera M, "Estrogenic ovulatory dysfunction or functional female hyperanfrogenism: an argument to discard the term polycystic ovary syndrome", Fertil Steril, 86, pp.1292~1295 (2006)
22. Azziz R, "Diagnostic criteria for polycyctic ovary syndrome: a reappraisal", Fertil Steril, 83, pp.1343~1346 (2005)
23. Geisthovel F, "The ESHRE", ASRM consensus on polycystic ovary syndrome(PCOS) --an extended critical analysis, 2007, pp.14, 522~535
24. Azziz R, "The prevalence and features of the polycystic ovary syndrome in an unselected population", J Clin Endocrinol Metab, 89, pp.2745~2749 (2004)
25. Carmina E, "Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome", Am J Obstet Gynecol, 167, pp.1807~1812 (1992)
26. Nestler JE, "Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome", N Engl J Med, 338, pp.1876~1880 (1998)
27. Azziz R, "Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial", J Clin Endocrinol Metab, 86, pp.1626~1632 (2001)
28. Welt CK, "Serum inhibin B in polycystic ovary syndrome: regulation by insulin and luteinizing hormone", J Clin Endocrinol Metab, 87, pp.5559~5565 (2002)
29. Goldzieher JW, "The polycystic ovary. VII. Intractable uterine bleeding and endometrial hyperplasia possibly related to an extraovarian source of oestrogen", Acta Endocrinol (Copenh), 54, pp.452~466 (1967)
30. Polson DW, "Polycystic ovaries--a common finding in normal women", Lancet, 1, pp.870~872 (1988)
31. Balen AH, "Ultrasound assessment of the polycystic ovary: international consensus definitions", Hum Reprod Update, 9, pp.505~514 (2003)
32. Webber LJ, "Formation and early development of follicles in the polycystic ovary", Lancet, 362, pp.1017~1021 (2003)
33. Falsetti L, "Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome", Contraception, 42, pp.611~619 (1990)
34. Sanchez LA, "Determining the time androgens and sex hormone-binding globulin take to return to baseline after discontinuation of oral contraceptives in women with polycystic ovary syndrome: a prospective study", Fertil Steril, 87, pp.712~714 (2007)
35. Waggoner W, "Total testosterone and DHEAS levels as predictors of androgen-secreting neoplasms: a populational study", Gynecol Endocrinol, 13, pp.394~400 (1999)
36. Lobo RA, "Ovarian hyperandrogenism and androgen-producing tumors", Endocrinol Metabol Clin North Am, 20, pp.773~805 (1991)
37. Azziz R, "Clinical review 56: nonclassic adrenal hyperplasia: current concepts", J Clin Endocrinol Metab, 78, pp.810~815 (1994)
38. Luciano AA, "Hyperprolactinemia in polycystic ovary syndrome", Fertil Steril, 41, pp.719~725 (1984)
39. Farquhar CM, "The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women", Aust N Z J Obstet Gynaecol, 34, pp.67~72 (1994)
40. Koivunen R, "The prevalence of polycystic ovaries in healthy women", Acta Obstet Gynecol Scand, 78, pp.137~141 (1999)
41. Vink JM, "Heritability of polycystic ovary syndrome in a Dutch twin-family study", J Clin Endocrinol Metab, 91, pp.2100~2104 (2006)
42. Kahsar-Miller MD, "Prevalence of polycystic ovary syndrome(PCOS) in first-degree relatives of patients with PCOS", Fertil Steril, 75, pp.53~58 (2001)
43. Legro RS, "Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome", Proc Natl Acad Sci USA, 95, pp.14956~14960 (1998)
44. Legro RS, "Elevated dehydroepiandrosterone sulfate levels as the reproductive phenotype in the brothers of women with polycystic ovary syndrome", J Clin Endocrinol Metab, 87, pp.2134~2138 (2002)
45. Legro RS, "Insulin resistance in the sisters of women with polycystic ovary syndrome: association with hyperandrogenemia rather than menstrual irregularity", J Clin Endocrinol Metab, 87, pp.2128~2133 (2002)
46. Norman RJ, "Hyperinsulinemia is common in family members of women with polycystic ovary syndrome", Fertil Steril, 66, pp.942~947 (1996)
47. Colilla S, "Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their first degree relatives", J Clin Endocrinol Metab, 86, pp.2027~2031 (2001)
48. Baillargeon JP, "Use of insulin sensitizers in polycystic ovarian syndrome", Curr Opin Investig Drugs, 6, pp.1012~1022 (2005)
49. Baillargeon JP, "Insulin sensitizers for polycystic ovary syndrome", Clin Obstet Gynecol, 46, pp.325~340 (2003)
50. Baillargeon JP, "Comparison of metformin and thiazolidinediones in the management of polycystic ovary syndrome", Curr Opin Endocrinol Diabetes, 9, pp.303~311 (2002)
51. Baillargeon JP, "Effects of metformin and rosiglitazone, alone and in combination, in lean women with polycystic ovary syndrome and normal indices of insulin sensitivity", Fertil Steril, 82, pp.893~902 (2004)
52. Baillargeon JP, "Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity", Fertil Steril, 88, pp.886~893 (2007)
53. Dunaif A, "Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome", Diabetes, 38, pp.1165~1174 (1989)
54. VrbIkova J, "Insulin sensitivity in women with polycystic ovary syndrome", J Clin Endocrinol Metab, 89, pp.2942~2945 (2004)
55. Ciampelli M, "Heterogeneity in beta cell activity, hepatic insulin clearance and peripheral insulin sensitivity in women with polycystic ovary syndrome", Hum Reprod, 12, pp.1897~1901 (1997)
56. Dunaif A, "Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome", J Clin Endocrinol Metab, 70, pp.699~704 (1990)
57. Ciaraldi TP, "Cellular insulin resistance in adipocytes from obese polycystic ovary syndrome subjects involves adenosine modulation of insulin sensitivity", J Clin Endocrinol Metab, 82, pp.1421~1425 (1997)
58. Nestler JE, "Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system", J Clin Endocrinol Metab, 83, pp.2001~2005 (1998)
59. Willis D, "Modulation by insulin of follicle-stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries", J Clin Endocrinol Metab, 81, pp.302~309 (1996)
60. Nelson-Degrave VL, "Alterations in mitogenactivated protein kinase kinase and extracellular regulated kinase signaling in theca cells contribute to excessive androgen production in polycystic ovary syndrome", Mol Endocrinol, 19, pp.379~390 (2005)
61. Kalme T, "Comparative studies on the regulation of insulin-like growth factorbinding protein-1 (IGFBP-1) and sex hormonebinding globulin(SHBG) production by insulin and insulin-like growth factors in human hepatoma cells", J Steroid Biochem Mol Biol, 86, pp.197~200 (2003)
62. Lord JM, "Metformin in polycystic ovary syndrome: systematic review and meta-analysis", BMJ, 327, pp.951~953 (2003)
63. Kashyap S, "Insulinsensitizing agents as primary therapy for patients with polycystic ovarian syndrome", Hum Reprod, 19, pp.2474~2483 (2004)
64. Waldstreicher J, "Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization", J Clin Endocrinol Metab, 66, pp.165~172 (1988)
65. Imse V, "Comparision of luteinizing hormone pulsatility in the serum of women suffering from polycystic ovarian disease using a bioassay and five different immunoassays", J Clin Endocrinol Metab, 74, pp.1053~1061 (1992)
66. Adashi EY, "Hypothalamic-pituitary dysfunction in polycystic ovarian disease", Endocrinol Metab Clin North Am, 17, pp.649~666 (1988)
67. Kiddy DS, "Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome", Clin Endocrinol (Oxf), 36, pp.105~111 (1992)
68. Balen AH, "Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients", Human Reprod, 10, pp.2107~2111 (1995)
69. Conway GS, "Insulin resistance and the polycystic ovary syndrome", Contemp Rev Obstet Gynaecol, 2, pp.34~39 (1990)
70. Hamilton-Fairley D, "Association of moderate obesity with poor pregnancy outcome in women with polycystic ovary syndrome treated with low dose gonadotropins", Br J Obstet Gynaecol, 99, pp.128~131 (1992)
71. National Collaborating Centre for Womens's and Children's Health, "Fertility : assessment and Treatment for People with Fertility Problems" (2004), RCOG Press
72. Cedergren MI, "Maternal morbid obesity and the risk of adverse pregnancy outcome", Obstet Gynecol, 103, pp.219~224 (2004)
73. Linné Y., "Effects of obesity on women’s reproduction and complications during pregnancy", Obes Rev, 5, pp.137~143 (2004)
74. Nestler JE, "Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome", N Engl J Med, 338, pp.1876~1880 (1998)
75. Diamamti-Kandarakis E, "Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome", Eur J Endocrinol, 138, pp.269~274 (1998)
76. Arlt W, "Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3betahydroxysteroid dehydrogenase", J Biol Chem, 267, pp.16767~16771 (2001)
77. Casper RF, "Review: aromatase inhibitors for ovulation induction", J Clin Endocrinol Metab, 91, pp.760~761 (2006)
78. Biljan MM, "The outcome of 150 babies following the treatment with letrozole or letrozole and gonadotropins", Fertil Steril, 84(Suppl 1), pp.S95~ (2005)
79. Hamilton-Fairley D, "Low-dose gonadotropin therapy for induction of ovulation in 100 women with polycystic ovary syndrome", Hum Reprod, 6, pp.1095~1099 (1991)
80. Gjönnaess H, "Polycystic ovarian syndrome treated by ovarian electrocautery through the laparoscope", Fertil Steril, 41, pp.20~25 (1984)
81. Daniell JF, "Polycystic ovaries treated by laparoscopic laser vaporization", Fertil Steril, 51, pp.232~236 (1989)
82. Balen AH, "A prospective study comparing unilateral and bilateral laparoscopic ovarian diathermy in women with the polycystic ovary syndrome", Fertil Steril, 62, pp.921~925 (1994)
83. Farquhar C, "Laparoscopic ‘drilling’ by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome", Cochrane Database Syst Rev, 18, pp.CD001122~ (2007)
84. Bayram N, "Using an electrocautery strategy or recombinant FSH to induce ovulation in polycystic ovary syndrome: a randomised controlled trial", BMJ, 328, pp.192~ (2004)
85. Child TJ, "A comparison of in vitro maturation and in vitro fertilization for women with polycystic ovaries", Obstet Gynecol, 100, pp.665~670 (2002)
86. Wang PH, "Androgens and ovarian cancers", Eur J Gynaecol Oncol, 25, pp.157~163 (2004)
87. Cheung AP, "Ultrasound and menstrual history in predicting endometrial hyperplasia in polycystic ovary syndrome", Obstet Gynecol, 98, pp.325~331 (2001)
88. Hardiman P, "Polycystic ovary syndrome and endometrial carcinoma", Lancet, 361, pp.1810~1812 (2003)
89. Pierpoint T, "Mortality of women with polycystic ovary syndrome at long-term followup", J Clin Epidemiol, 51, pp.581~586 (1998)
90. Wild S, "Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study", Hum Fertil (Camb), 3, pp.101~105 (2000)
91. Resta L, "Morphologic precursors of ovarian epithelial tumors", Obstet Gynecol, 82, pp.181~186 (1993)
92. Schildkraut JM, "Epithelial ovarian cancer risk among women with polycystic ovary syndrome", Obstet Gynecol, 88(4 Pt 1), pp.554~559 (1996)
93. DeUgarte CM, "Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment", Fertil Steril, 83, pp.1454~1460 (2005)
94. Legro RS, "Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone", J Clin Endocrinol Metab, 88, pp.5137~5144 (2003)
95. Apridonidze T, "Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome", J Clin Endocrinol Metab, 90, pp.1929~1935 (2005)
96. Ford ES, "Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey", JAMA, 287, pp.356~359 (2002)
97. Wild RA, "Lipoprotein lipid concentration and cardiovascular risk in women with polycystic ovary syndrome", J Clin Endocrinol Metab, 61, pp.946~951 (1985)
98. Legro RS, "Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome", Am J Med, 111, pp.607~613 (2001)
99. Talbott EO, "Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome", J Clin Endocrinol Metab, 89, pp.5454~5461 (2004)
100. Diamanti-Kandarakis E, "Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin", Hum Reprod, 21, pp.1426~1431 (2006)
101. Morin-Papunen L, "Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome", J Clin Endocrinol Metab, 88, pp.4649~4654 (2003)
102. Orio F Jr, "Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study", J Clin Endocrinol Metab, 90, pp.6072~6076 (2005)

관련 논문AI추천